<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">J Thouvenin</style></author><author><style face="normal" font="default" size="100%">C Van Marcke</style></author><author><style face="normal" font="default" size="100%">L Decoster</style></author><author><style face="normal" font="default" size="100%">Gordana Raicevic</style></author><author><style face="normal" font="default" size="100%">K Punie</style></author><author><style face="normal" font="default" size="100%">Marc Van den Bulcke</style></author><author><style face="normal" font="default" size="100%">R Salgado</style></author><author><style face="normal" font="default" size="100%">Els Van Valckenborgh</style></author><author><style face="normal" font="default" size="100%">B Maes</style></author><author><style face="normal" font="default" size="100%">S Joris</style></author><author><style face="normal" font="default" size="100%">D Vander Steichel</style></author><author><style face="normal" font="default" size="100%">K Vranken</style></author><author><style face="normal" font="default" size="100%">S Jacobs</style></author><author><style face="normal" font="default" size="100%">F Dedeurwaerdere</style></author><author><style face="normal" font="default" size="100%">G Martens</style></author><author><style face="normal" font="default" size="100%">H Devos</style></author><author><style face="normal" font="default" size="100%">F P Duhoux</style></author><author><style face="normal" font="default" size="100%">M Rasschaert</style></author><author><style face="normal" font="default" size="100%">P Pauwels</style></author><author><style face="normal" font="default" size="100%">K Geboes</style></author><author><style face="normal" font="default" size="100%">J Collignon</style></author><author><style face="normal" font="default" size="100%">S Tejpar</style></author><author><style face="normal" font="default" size="100%">J-L Canon</style></author><author><style face="normal" font="default" size="100%">Michael Peeters</style></author><author><style face="normal" font="default" size="100%">A Rutten</style></author><author><style face="normal" font="default" size="100%">T Van de Mooter</style></author><author><style face="normal" font="default" size="100%">J Vermeij</style></author><author><style face="normal" font="default" size="100%">D Schrijvers</style></author><author><style face="normal" font="default" size="100%">W Demey</style></author><author><style face="normal" font="default" size="100%">W Lybaert</style></author><author><style face="normal" font="default" size="100%">J Van Huysse</style></author><author><style face="normal" font="default" size="100%">J Mebis</style></author><author><style face="normal" font="default" size="100%">A Awada</style></author><author><style face="normal" font="default" size="100%">K B M Claes</style></author><author><style face="normal" font="default" size="100%">Aline Hébrant</style></author><author><style face="normal" font="default" size="100%">J Van der Meulen</style></author><author><style face="normal" font="default" size="100%">B Delafontaine</style></author><author><style face="normal" font="default" size="100%">I Vanden Bempt</style></author><author><style face="normal" font="default" size="100%">J Maetens</style></author><author><style face="normal" font="default" size="100%">Maïté de Hemptinne</style></author><author><style face="normal" font="default" size="100%">S Rottey</style></author><author><style face="normal" font="default" size="100%">P Aftimos</style></author><author><style face="normal" font="default" size="100%">J De Grève</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">PRECISION: the Belgian molecular profiling program of metastatic cancer for clinical decision and treatment assignment.</style></title><secondary-title><style face="normal" font="default" size="100%">ESMO Open</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Belgium</style></keyword><keyword><style  face="normal" font="default" size="100%">Genomics</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">Medical Oncology</style></keyword><keyword><style  face="normal" font="default" size="100%">Neoplasms</style></keyword><keyword><style  face="normal" font="default" size="100%">Precision Medicine</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2022</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2022 Aug</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">7</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;PRECISION is an initiative from the Belgian Society of Medical Oncology (BSMO) in collaboration with several stakeholders, encompassing four programs that aim to boost genomic and clinical knowledge with the ultimate goal to offer patients with metastatic solid tumors molecularly guided treatments. The PRECISION 1 study has led to the creation of a clinico-genomic database. The Belgian Approach for Local Laboratory Extensive Tumor Testing (BALLETT) and GeNeo studies will increase the number of patients with advanced cancer that have comprehensive genotyping of their cancer. The PRECISION 2 project consists of investigator-initiated phase II studies aiming to provide access to a targeted drug for patients whose tumors harbor actionable mutations in case the matched drug is not available through reimbursement or clinical trials in Belgium.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">4</style></issue></record></records></xml>